I had dinner over the weekend with a close friend who is a breast cancer survivor (her word) and a former avid participant in the annual marathons sponsored by the Susan B. Komen Foundation. Her status as a former activist was new. “Is this what we were racing for?” she said. She is skeptical by nature, and the brouhaha over Komen’s back-and-forth over funding Planned Parenthood last week didn’t make her angry. It merely flipped the switch that changes skepticism into cynicism. To paraphrase the old Phil Ochs song, she ain’t a marchin’ anymore.
SonoSite (NSDQ: SONO) said it’s replacing retiring CFO Marcus Smith with Anil Amlani, head of its VisualSonics subsidiary.
Smith’s last day as the ultrasound device maker’s top financial mind is today; he’s slated to stay on at the Bothell, Wash.-based company until Jan. 5, according to a press release.
Smith had been with SonoSite since 2007, according to the release.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Accuray (NSDQ:ARAY) shares are down today after the radiosurgery company reported surging first-quarter sales and beat Wall Street’s earnings expectations, as investors reacted to net losses of nearly six times the Q1 2011 mark.
Accuray reported losses of $26.5 million, or 38 cents per share, on sales of $100.5 million for the three months ended Sept. 30. That’s top-line growth of 163.9 percent compared with the same period last year, largely due to the massive infusion that followed ARAY’s acquisition of rival TomoTherapy earlier this year.
Hologic (NSDQ:HOLX) shares are down more than 3 percent this morning after a decision by an affiliate of health insurer Wellpoint that its Selenia Dimensions 3D mammography system is "investigational and not medically necessary."
HOLX shares were trading at $15.07 as of about 10:15 a.m. today, down 3.0 percent from their $15.54 close Friday.
GE Healthcare, a unit of General Electric Company (NYSE: GE) landed FDA 510(k) clearance for its SenoBright contrast enhanced spectral mammography for breast cancer diagnosis.
Launched in 2010, the SenoBright system is already used in France, Spain, Italy, Belgium, Germany, Austria and Japan.